Brought to you by 
ValenTx brings in $20.3mm through second equity round
10 Sep 2009
Executive Summary
ValenTx (minimally invasive treatments for morbid obesity) has raised $20.3mm in its Series B financing of preferred shares. SV Life Sciences led and was joined by other first-time backer Covidien Ventures and returning shareholders Sapient Capital, EDF Ventures, Kaiser Permanente Ventures, Affinity Capital Partners, and TGap Ventures. A total of 24 investors participated in the round, which could bring in an additional $1.7mm.
Deal Industry
- Medical Devices
-
Medical Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Surgical Equipment & Devices
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ValenTx brings in $20.3mm through second equity round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice